\square

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	APPROVAL							
OMB Number:	3235-0287							
Estimated average burden								
hours per resp	onse: 0.5							

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

						000000	1100(11) 01 110	envesunen		inpuny / tot								
1. Name and Address of Reporting Person [*] Quaggin Susan E					2. Issuer Name and Ticker or Trading Symbol <u>AbbVie Inc.</u> [ABBV]									5. Relationship of Reporting Person(s) to Issue (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year) 12/31/2023									-	give title		Other (s below)	
1 N. WAUKEGAN ROAD				4. li	4. If Amendment, Date of Original Filed (Month/Day/Year)									 Individual or Joint/Group Filing (Check Applicabl Line) 				plicable	
(Street) NORTH IL 60064				-										X Form filed by One Reporting Person Form filed by More than One Reporting Person					
CHICAC	30 ¹¹			- Ri	Rule 10b5-1(c) Transaction Indication														
(City)	(S	tate)	(Zip)		Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.											ed to			
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) Date (Month/D					ar) E	2A. Deemed Execution Date, if any (Month/Day/Year		Code (I	Transaction Dispose Code (Instr. 5)		ities Acqui d Of (D) (Ir				es For ially (D) Following (I)		r Indirect I str. 4)	7. Nature of Indirect Beneficial Ownership	
									Code	v	Amount	(A) ((D)	Pr Pr	ice	Transac	eported ansaction(s) astr. 3 and 4)			Instr. 4)
		Т							quired, D s, option						Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year		4. Transactic Code (Inst r) 8)				6. Date Exe Expiration (Month/Day	Date		and 7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable		xpiration	Title	Amo or Num of Shar	ber					
Stock Equivalent Units	\$154.97	12/31/2023			Α		64		(1)		(1)	Common Stock	64	4	\$154.97	64		D	

Explanation of Responses:

1. Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

	2/2024
T.O. Odutayo, Attorney-in-Fact for Susan E. Quaggin	<u>3/2024</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.